Human PLA2G1B / PLA2 Protein (His Tag)
PLA2,PLA2A,PPLA2
- 100ug (NPP4173) Please inquiry
| Catalog Number | P10865-H08H |
|---|---|
| Organism Species | Human |
| Host | Human Cells |
| Synonyms | PLA2,PLA2A,PPLA2 |
| Molecular Weight | The recombinant human PLA2G1B comprises 144 amino acids after removal of the signal peptide, and has a predicted molecular mass of 16.2 kDa. rh PLA2G1B migrates as an approximately 19 kDa band in SDS-PAGE under reducing conditions. |
| predicted N | Asp 16 |
| SDS-PAGE |  |
| Purity | > 92 % as determined by SDS-PAGE |
| Protein Construction | A DNA sequence encoding the human PLA2G1B (NP_000919.1) (Met 1-Ser 148) with a C-terminal polyhistidine tag was expressed. |
| Bio-activity | Measured by its ability to hydrolyze 1-Hexadecanoyl-2-(1-pyrenedecanoyl)-sn-glycero-3-phosphomethanol. The specific activity is >2,500 pmol/min/μg. |
| Research Area | Signaling |Signal Transduction |Signaling Pathway |Lipid Signaling |PLA |
| Formulation | Lyophilized from sterile 10mM Tris, 5mM CaCl2, pH 8.0 1. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA. |
| Background | Mouse phospholipase A2, also known as Phosphatidylcholine 2-acylhydrolase 1B, Group IB phospholipase A2, PLA2 and PLA2G1B, is a secreted protein which belongs to the phospholipase A2 family. Phospholipase A2 / PLA2G1B catalyzes the release of fatty acids from glycero-3-phosphocholines. The best known varieties are the digestive enzymes secreted as zymogens by the pancreas of mammals. Sequences of pancreatic Phospholipase A2 / PLA2G1B enzymes from a variety of mammals have been reported. One striking feature of these enzymes is their close homology to venom phospholipases of snakes. Other forms of Phospholipase A2 / PLA2G1B have been isolated from brain, liver, lung, spleen, intestine, macrophages, leukocytes, erythrocytes, inflammatory exudates, chondrocytes, and platelets. Mice lacking in Phospholipase A2 / PLA2G1B are resistant to obesity and diabetes induced by feeding a diabetogenic high-fat/high-carbohydrate diet. Oral supplementation of a diabetogenic diet with the PLA2G1B inhibitor methyl indoxam effectively suppresses diet-induced obesity and diabetes. PLA2G1B inhibition may be a potentially effective oral therapeutic option for treatment of obesity and diabetes. |
| Reference |